Comparing Thrombectomy System Options for Venous Thromboembolism
Venous thromboembolism (VTE), a condition encompassing both deep vein thrombosis (DVT) and pulmonary embolism (PE), represents a significant global health concern, affecting millions of people annually. While anticoagulation therapy has traditionally been the cornerstone of VTE management, recent advancements in medical technology have led to the development of innovative treatment modalities, including percutaneous mechanical thrombectomy (PMT). This article provides a comprehensive overview of the current landscape of thrombectomy systems for VTE, comparing their mechanisms of action, clinical applications, and available evidence on their effectiveness. This information is intended for educational purposes for both patients and healthcare professionals and should not be considered medical advice.
Understanding Venous Thromboembolism and the Need for Advanced Treatments
Deep vein thrombosis occurs when a blood clot, or thrombus, forms in a deep vein, most commonly in the legs. If a portion of this clot breaks off and travels to the lungs, it can cause a life-threatening pulmonary embolism. The primary goals of VTE treatment are to prevent the thrombus from growing, to prevent it from embolizing to the lungs, and to reduce the risk of long-term complications such as post-thrombotic syndrome (PTS), a chronic condition characterized by pain, swelling, and skin changes in the affected limb.
While anticoagulants are effective in preventing new clot formation, they do not actively remove existing thrombi. Catheter-directed thrombolysis (CDT), which involves the infusion of clot-dissolving drugs directly into the thrombus, has been shown to be effective in rapidly restoring blood flow. However, CDT is associated with an increased risk of bleeding, including intracranial hemorrhage [1]. This has driven the development of mechanical thrombectomy devices, which aim to physically remove the clot without the need for thrombolytic drugs.
The Landscape of Thrombectomy Systems
Percutaneous mechanical thrombectomy (PMT) has emerged as a promising alternative to traditional therapies, offering the potential for rapid clot removal with a lower risk of bleeding complications [1]. PMT devices can be broadly categorized based on their mechanism of action:
- **Aspiration Thrombectomy:** These devices use suction to directly extract the thrombus from the blood vessel. They are generally most effective for fresh, or acute, thrombi that have not yet adhered firmly to the vessel wall.
- **Mechanical Fragmentation:** These systems employ various mechanical means, such as rotating wires or jets of saline, to break the clot into smaller fragments that can then be aspirated or cleared by the body\'s natural processes.
- **Rheolytic Thrombectomy:** This technique utilizes high-velocity jets of saline to create a vortex that macerates and aspirates the thrombus. The AngioJet™ system is a well-known example of a rheolytic thrombectomy device.
The choice of thrombectomy system depends on several factors, including the age and characteristics of the thrombus. Acute thrombi, which are soft and gelatinous, are more amenable to aspiration, while older, more organized chronic thrombi may require mechanical fragmentation or rheolytic approaches for effective removal [1].
Comparing the Effectiveness of Thrombectomy Devices
Recent studies have begun to shed light on the comparative effectiveness of different thrombectomy devices. A retrospective cohort study by Mittleider et al. compared three commonly used devices: the AngioJet™ ZelanteDVT™ (AJ), the ClotTriever® System (CT), and the Indigo® System (IN) [2]. The study, which analyzed data from the PINC AI™ Healthcare Database, found that the ClotTriever® System was associated with lower in-hospital mortality compared to the AngioJet™ and Indigo® systems. Furthermore, the use of concomitant thrombolytic therapy was significantly lower in the ClotTriever® group (8.9%) compared to the AngioJet™ (61.6%) and Indigo® (37.8%) groups. Patients treated with the ClotTriever® system also had lower rates of post-procedure blood transfusions and were associated with lower hospital costs and shorter lengths of stay [2].
Another study comparing mechanical thrombectomy to catheter-directed thrombolysis found that MT was associated with greater periprocedural thrombus reduction, shorter length of stay, and improved symptoms at 12 months [2]. These findings suggest that mechanical thrombectomy, particularly with devices that minimize the need for thrombolytics, may offer a safer and more cost-effective approach to the treatment of DVT.
The Future of VTE Treatment
The field of VTE treatment is rapidly evolving, with ongoing research focused on optimizing device selection, patient outcomes, and long-term results. The DEFIANCE randomized controlled trial, which is currently underway, will provide further insights into the role of mechanical thrombectomy compared to anticoagulation alone in the treatment of DVT [2]. As our understanding of the comparative effectiveness of different thrombectomy systems grows, we can expect to see a continued shift towards more personalized and minimally invasive approaches to VTE management.
Disclaimer
This article is for informational purposes only and does not constitute medical advice. The information contained herein is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read in this article.
References
[1] Ogbonna, B., Monroe, E., Shin, D., Chick, J. F. B., & Meram, E. (2025). Venous thrombectomy: Device landscape and applications. *Clinical Imaging*, *121*, 110462. https://doi.org/10.1016/j.clinimag.2025.110462
[2] Finn, M. T. (2024). Comparative Effectiveness of Thrombectomy Devices in Deep Vein Thrombosis: A Step Forward. *J Soc Cardiovasc Angiogr Interv*, *3*(8), 102238. https://doi.org/10.1016/j.jscai.2024.102238